Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | MGMT | P16455 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465696 | 0.86 | APP (0.59) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL8990589 | 0.82 | APP (0.71) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL8990659 | 0.82 | ADORA3 (0.56) | APPADORA1ADORA2AADORA2BADORA3 | |
| Hydrochloric Acid SCHEMBL5471522 | 0.81 | APP (0.69) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL22151175 | 0.78 | APP (0.64) | APPADORA1ADORA2AADORA2BADORA3 | |
| Sulfuric Acid SCHEMBL5463730 | 0.78 | APP (0.61) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2451092 | 0.77 | APP (0.64) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL21055814 | 0.71 | APP (0.68) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL9792866 | 0.71 | APP (0.57) | APPADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL1938196 | 0.71 | HTR7 (0.56) | APPADORA1ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| US-5500428-A | Furyl-substituted purines and adenosine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-5300509-A | Adenosine antagonists for treating cardiovascular disorders, vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-05 | — | — | US | disclosed |
| EP-0544445-A2 | Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists | ZENECA LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | APP 760/4885ADORA1 663/4885ADORA2A 747/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | APP 487/4885ADORA1 620/4885ADORA2A 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.